Risk management model in patients receiving therapy with biotechnological medications for rheumatoid arthritis in a medical center in Barranquilla, Colombia

Abstract

Introduction: Rheumatoid arthritis is an autoimmune, chronic and inflammatory disease that mainly the synovial membrane of the joints. Clinical features are pain, inflammation, heat and stiffness of the joints. Objective: Identification of the problems related to the use of biotechnological medicines and the negative results associated with them. Results: 78 patients (91.02% women and 9.8% men) were included where the most commonly used biological medicines were Etanercept (52.5%) Adalimumab (14.10) and Tocilizumab (15.3) and Tofacitinib (3.8%) Rituximab, Golimumab (5.12%) abatacept (3.84%) and certolizumab (1.84%). 96 NCO were identified in 49 patients of which 11 are problems of need, 28 effectiveness problems and 57 safety problems. Conclusion: The identification of medication-related problems and the resolution and prevention of negative results associated with medication allows us to obtain better results in the pharmacotherapy of the patient, improving their quality of life.